Abstract
Histone deacetylase (HDAC) inhibitors are emerging as a novel class of anti-tumor agents and have manifested the ability to decrease proliferation and increase apoptosis in different cancer cells. A significant number of genes have been identified as potential effectors responsible for the anti-tumor function of HDAC inhibitor. However, the molecular mechanisms of these HDAC inhibitors in this process remain largely undefined. In the current study, we searched for microRNAs (miRs) that were affected by HDAC inhibitor trichostatin (TSA) and investigated their effects in endometrial cancer (EMC) cells. Our data showed that TSA significantly inhibited the growth of EMC cells and induced their apoptosis. Among the miRNAs that altered in the presence of TSA, the miR-106b-93-25 cluster, together with its host gene MCM7, were obviously down-regulated in EMC cells. p21 and BIM, which were identified as target genes of miR-106b-93-25 cluster, increased in TSA treated tumor cells and were responsible for cell cycle arrest and apoptosis. We further identified MYC as a regulator of miR-106b-93-25 cluster and demonstrated its down-regulation in the presence of TSA resulted in the reduction of miR-106b-93-25 cluster and up-regulation of p21 and BIM. More important, we found miR-106b-93-25 cluster was up-regulated in clinical EMC samples in association with the overexpression of MCM7 and MYC and the down-regulation of p21 and BIM. Thus our studies strongly indicated TSA inhibited EMC cell growth and induced cell apoptosis and cell cycle arrest at least partially through the down-regulation of the miR-106b-93-25 cluster and up-regulation of it's target genes p21 and BIM via MYC.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Apoptosis / drug effects*
-
Apoptosis / genetics
-
Apoptosis Regulatory Proteins / genetics
-
Apoptosis Regulatory Proteins / metabolism
-
Bcl-2-Like Protein 11
-
Cell Cycle Proteins / genetics
-
Cell Cycle Proteins / metabolism
-
Cell Line, Tumor
-
Cell Proliferation / drug effects
-
Cyclin-Dependent Kinase Inhibitor p21 / genetics
-
Cyclin-Dependent Kinase Inhibitor p21 / metabolism
-
DNA-Binding Proteins / genetics
-
DNA-Binding Proteins / metabolism
-
Down-Regulation / drug effects
-
Down-Regulation / genetics*
-
E-Box Elements / genetics
-
Endometrial Neoplasms / genetics*
-
Endometrial Neoplasms / pathology*
-
Female
-
Gene Expression Regulation, Neoplastic / drug effects
-
Humans
-
Hydroxamic Acids / pharmacology*
-
Membrane Proteins / genetics
-
Membrane Proteins / metabolism
-
MicroRNAs / genetics*
-
MicroRNAs / metabolism
-
Minichromosome Maintenance Complex Component 7
-
Multigene Family / genetics
-
Nuclear Proteins / genetics
-
Nuclear Proteins / metabolism
-
Promoter Regions, Genetic / genetics
-
Proto-Oncogene Proteins / genetics
-
Proto-Oncogene Proteins / metabolism
-
Proto-Oncogene Proteins c-myc / genetics*
-
Proto-Oncogene Proteins c-myc / metabolism
-
RNA, Messenger / genetics
-
RNA, Messenger / metabolism
Substances
-
Apoptosis Regulatory Proteins
-
BCL2L11 protein, human
-
Bcl-2-Like Protein 11
-
Cell Cycle Proteins
-
Cyclin-Dependent Kinase Inhibitor p21
-
DNA-Binding Proteins
-
Hydroxamic Acids
-
MIRN106 microRNA, human
-
Membrane Proteins
-
MicroRNAs
-
Nuclear Proteins
-
Proto-Oncogene Proteins
-
Proto-Oncogene Proteins c-myc
-
RNA, Messenger
-
trichostatin A
-
MCM7 protein, human
-
Minichromosome Maintenance Complex Component 7
Grants and funding
This study was funded by National High Technology Research and Development Program of China grant 2007AA021104 (A.G. Yang), National Basic Research Program of China 2010CB529905 (L.T. Jia), National Major Science and Technology Specialized Project for New Drugs Formulation 2009ZX09103-664 (L.T. Jia), Natural Science Foundation of China 81172289 (T. Wang). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.